REG - Immupharma PLC - Result of AGM

ImmuPharmaAnnouncement

28/06/2022 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220628:nRSb4745Qa&default-theme=true

RNS Number : 4745Q  Immupharma PLC  28 June 2022

 

 

RNS:
RELEASE
28 June 2022

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2022 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, held its AGM earlier today. The Company is pleased to announce that
all resolutions were duly passed, details of which are contained in the table
below.

ImmuPharma's Chairman & CEO, Tim McCarthy said: "We are delighted to have
had such overwhelming support from right across our shareholder base. This
includes corporate, institutional and long-term private shareholders, in
respect to all of the AGM resolutions. The support for the re-appointment of
the new Board, an integral part of the management restructuring, successfully
completed in August last year, being part of the resolutions being approved.

 

Importantly, we also announced yesterday, a key progress update on our lead
programme, Lupuzor™. Our partner, Avion Pharmaceuticals, who is also a major
supportive shareholder, has confirmed that having met all the Food and Drug
Administration's ("FDA") requirements, they have sought final guidance from
the FDA, as they actively prepare for the start of the international Phase 3
trial of Lupuzor™ in Lupus patients. This is a key inflection point for the
positive progress of Lupuzor™ towards becoming a first line therapy to many
Lupus sufferers globally.

 

On behalf of the new Board, I would like to thank all our shareholders and
collaborators for their continued belief in ImmuPharma."

 

 

 

 Resolution                                                                       For         % For  Against  % Against  Withheld
 1. To receive the accounts of the Company for the year ended 31 December 2021    53,394,853  99.14  463,666  0.86       837,178
 together with the reports thereon of the directors and auditors of the Company

 2. To re-appoint Tim McCarthy as a director of the Company                       53,310,582  98.99  542,318  1.01       842,797

 3. To re-appoint Dr Tim Franklin as a director of the Company                    53,300,349  99.00  540,213  1.00       855,135

 4. To re-appoint Dr Sanjeev Pandya as a director of the Company                  53,304,688  99.00  535,874  1.00       855,135

 5. To re-appoint Lisa Baderoon as a director of the Company                      53,304,363  99.00  536,199  1.00       855,135

 6. To re-appoint Nexia Smith & Williams as auditors of the Company               53,280,466  99.02  527,057  0.98       888,174

 7. That subject to the passing of resolution 10, each ordinary share of £0.10    53,000,307  98.47  821,831  1.53       873,559
 in the capital of the Company be sub-divided into one ordinary share of £0.01

 each and one deferred share of £0.09 each
 8. That the Directors be authorised for the purpose of Section 551 of the        52,999,192  98.58  765,320  1.42       931,185
 Companies Act 2006 (the "Act") to allot shares on the basis as set out in the

 Notice of Meeting. Special Resolution
 9. That, subject to the passing of Resolution 8, the Directors are hereby        52,972,066  98.53  792,446  1.47       931,185
 empowered pursuant to section 571 of the Act to allot equity securities on the

 basis as set out in the Notice of Meeting
 10. That, subject to the passing of resolution 7, the articles of association    52,992,957  98.56  772,458  1.44       930,282
 of the Company be amended as set out in the Notice of Meeting

 

 

As at the date of the AGM, the number of issued ordinary shares of the Company
was 284,984,933 shares, which was the total number of shares entitling the
holders to attend and vote for or against all resolutions. In accordance with
the Company's Articles of Association, every member has one vote for every
share held. Votes withheld are not votes in law and have not been counted in
the calculation of the proportion of vote "for" or "against" a
resolution. Proxy appointments which gave discretion to the Chairman have
been included in the "for" total.

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

Ends

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )        +44 (0) 207 206 2650

 Tim McCarthy, Chairman and Chief Executive Officer
 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 (0) 20 3650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                               +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, Lupuzor™, within our P140 platform, is a
first-in class autophagy immunomodulator which is in Phase 3 for the treatment
of Lupus, a debilitating and potentially life threatening auto immune disease.
Preclinical analysis suggests therapeutic activity for many other autoimmune
diseases targeted through our P140 platform, that share the same autophagy
mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGDZGZVGRMGZZM